Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials

Patent metadata

Field	Value
Publication number	US-10294195-B2
Application number	US-201515115331-A
Country	US
Kind code	B2
Filing date	Jan 30, 2015
Priority date	Jan 31, 2014
Publication date	May 21, 2019
Grant date	May 21, 2019

Abstract

The invention provides a diamine crosslinking agent for acidic polysaccharides consisting of a diamine compound having a primary amino group at both terminals and an ester or thioester bond in the molecule, wherein the number of atom in the linear chain between at least one of the amino groups and the carbonyl carbon in the ester or thioester is 1 to 5; in particular, a diamine crosslinking agent for acidic polysaccharides which is represented by the general formula (I) below:

[the symbols in the formula are as described in the specification]; a crosslinked acidic polysaccharide obtained by forming crosslinks by amide bonding between the amino groups in the diamine crosslinking agent and carboxyl groups in an acidic polysaccharide; and a medical material including the crosslinked product.

First claim

The invention claimed is:

1. A method for preventing tissue adhesion, the method comprising a step of administering a crosslinked acidic polysaccharide to a surgical area of an individual,
wherein the crosslinked acidic polysaccharide is obtained by forming crosslinks by amide bonding between primary amino groups in a diamine crosslinking agent and carboxyl groups in an acidic polysaccharide;
wherein the acidic polysaccharide is chondroitin sulfate;
wherein the diamine crosslinking agent consists of diamine compounds having a primary amino group at both terminals and an ester or thioester bond; and
wherein the ester or thioester bond is component of a linear chain connecting the two terminal amino groups.

2. The method for preventing adhesion according to claim 1 , wherein the diamine crosslinking agent has the general formula (I) below:

wherein the number of atoms in the linear chain between the primary amino groups at both terminals is 5 to 12, X and Y are each independently a single bond, a substituted or unsubstituted alkanediyl group, a substituted or unsubstituted alkenylene group, or a substituted or unsubstituted alkynylene group, with the proviso that X and Y are not single bonds at the same time;
Z is an oxygen atom or a sulfur atom;
R 1 and R 2 are each independently a hydrogen atom, a —CONR 3 R 4 group, a —COOR 5 group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group,
any —CH 2 — in X or Y, if present, contains optionally substitution of one or more groups selected from the group consisting of an amide group (—CONH—), an ester group (—C(═O)—O—), an ether group (—O—), an imino group (—NH—) and a phenylene group, wherein the ester group, the amide group, the ether group or the imino group present in X or Y is not directly adjacent to —CO—Z— in the formula (I),
any —CH 2 — in R 1 or R 2 , if present, contains optionally substitution of one or more groups selected from the group consisting of >C═O, —CONH—, arylene, —O—, —NR 6 — and —S—;
the substituent in each of X and Y is selected from the group consisting of an hydroxyl group, an alkyl group having 1 to 6 carbon atoms, a phenyl group, an indolyl group, a diazolyl group, a —(CH 2 ) n —NHMe group, a —(CH 2 ) n —NMe 2 group, a —(CH 2 ) n —CONR 3 R 4 group, a —(CH 2 ) n —COOR 5 group, a —S-Me group, —SH group, 4-hydroxyphenyl group, a halogen atom, a nitro group, and a nitrile group, wherein n independently at each occurrence is an integer of 0 to 4;
the substituent in R 1 and R 2 is selected from the group consisting of an hydroxyl group, an alkyl group having 1 to 6 carbon atoms, a phenyl group, an indolyl group, a diazolyl group, a —(CH 2 ) n —NHMe group, a —(CH 2 ) n —NM 2 group, a —(CH 2 ) n —CONR 3 R 4 group, a —(CH 2 ) n —COOR 5 group, a —S-Me group and a —SH group, wherein n is, independently, an integer of 0 to 4; and
R 3 , R 4 , R 5 and R 6 are each, independently, a hydrogen atom or an alkyl group that contains optionally substitution of.

3. The method according to claim 2 , wherein Z is an oxygen atom.

4. The method according to claim 3 , wherein the number of atoms in the linear chain between the primary amino groups at both terminals is 5 to 8.

5. The method according to claim 3 , wherein the number of atoms in the linear chain between the primary amino groups at both terminals is 5 or 6.

6. The method according to claim 2 , wherein
R 1 is a hydrogen atom, or a substituted or unsubstituted alkyl group;
R 2 is a hydrogen atom, a —CONR 3 R 4 group or a —COOR 5 group;
X is a single bond or an alkanediyl group which a contains optionally substitution of a halogen;
Y is a substituted or unsubstituted alkanediyl group;
the substituent(s) in R 1 is selected from the group consisting of a methyl group, a phenyl group, an indolyl group, a —COOR 5 group and a —S-Me group; and
the substituent(s) in Y is selected from the group consisting of a methyl group, a phenyl group and a —COOR 5 group.

7. The method according to claim 2 , wherein
X is a single bond; Y is a >CR 7 R 8 group; and
R 7 and R 8 are each independently a hydrogen atom, a hydroxyl group, an alkyl group having 1 to 6 carbon atom, a phenyl group, a 4-hydroxyphenyl group, an indolyl group, a diazolyl group, a —(CH 2 ) n —NHMe group, a —(CH 2 ) n —NMe 2 group, a —(CH 2 ) n —CONR 3 R 4 group, a —(CH 2 ) n —COOR 5 group, a —SH group, a halogen atom, a nitro group or a nitrile group.

8. The method according to claim 7 , wherein
R 2 is a —CONR 3 R 4 group or a —COOR 5 group;
R 7 is a hydrogen atom; and
R 8 is a hydrogen atom or a methyl group.

9. The method according to claim 4 , wherein at least one of X and Y contains substitution of a phenyl group, a 4-hydroxyphenyl group, a —CONR 3 R 4 group, a —COOR 5 group, a halogen atom, a nitro group or a nitrile group.

10. The method according to claim 7 , wherein R 7 and R 8 are each independently a hydrogen atom, a phenyl group, a 4-hydroxyphenyl group, a —CONR 3 R 4 group, a —COOR 5 group, a halogen atom, a nitro group or a nitrile group.

11. The method according to claim 10 , wherein R 1 is a hydrogen atom, a —(CH 2 ) 2 —S—CH 3 group, a —(CH 2 ) 3 or 4 —NHMe group, a —(CH 2 ) 3 or 4 —NMe 2 group or a —(CH 2 ) 1 or 2 —COOR 5 group.

12. The method according to claim 11 , wherein R 2 is a —CONR 3 R 4 group or a —COOR 5 group, and R 7 and R 8 are hydrogen atoms.

13. The method according to claim 12 , wherein R 1 is a hydrogen atom.

14. The method according to claim 10 , wherein the diamine crosslinked agent has the general formula (II) below:

wherein R 1 is a hydrogen atom, a —CONR 3 R 4 group, a —COOR 5 group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group;
R 2′ is a —CONR 3 R 4 group or a —COOR 5 group;
any —CH 2 — in R 1 , if present, contains optionally substitution of one or more groups selected from the group consisting of a >C═O, an —CONH—, an arylene, an —O—, an —NR 6 — and a —S—(with the proviso that when R 5 is a benzyl group, the —O— is excluded);
the substituent(s) in R 1 is selected from the group consisting of a hydroxyl group, an alkyl group having 1 to 6 carbon atom, an indolyl group, a diazolyl group, a —(CH 2 ) n —NHMe group, a —(CH 2 ) n —NMe 2 group, a —(CH 2 ) n —CONR 3 R 4 group, a —(CH 2 ) n —COOR 5 group and a —SH group (with the proviso that when R 2′ is a —CONH 2 group, the —SH group is excluded) wherein n independently at each occurrence is an integer of 0 to 4;
R 3 , R 4 , R 5 and R 6 are each independently a hydrogen atom or an alkyl group that contains optionally substitution of a phenyl group; and
R 8′ is a hydrogen atom or a methyl group.

Assignees

• Seikagaku Kogyo Co Ltd

Inventors

• Funayama Sho
• Yasuda Yosuke
• Takezawa Akihiro
• Takahashi Katsuya

Classifications

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• C08K5/175

  containing COOH-groups; Esters or salts thereof · CPC title

• C08K5/20

  Carboxylic acid amides · CPC title

• C07C2601/02

  with a three-membered ring · CPC title

• C08B37/0072

  Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates · CPC title